Skip to main content
. 2023 Mar 25;27(3):102759. doi: 10.1016/j.bjid.2023.102759

Fig. 1.

Fig 1

Percentage of all (A) and MDR (B) Enterobacterales isolates susceptible to ceftazidime-avibactam divided into two 3-year time periods, 2015‒2017 and 2018‒2020, by country of isolation.